Siege Of Mumbai Affects Workers At Two Japanese Pharmas In India
This article was originally published in PharmAsia News
The terrorist siege of Mumbai, India, disrupted employee travel for several drug makers, including Daiichi Sankyo and Astellas Pharma. Both Japanese drug makers have subsidiaries based in India's financial capital. Daiichi ordered its employees on business trips to the area to return to Japan, while Astellas' few workers in a nascent marketing firm in the city were instructed to stay home. Several Daiichi personnel were in Mumbai to establish ties with Ranbaxy Laboratories, which Daiichi is converting into a subsidiary after buying the firm. (Click here for more - a subscription may be required
You may also be interested in...
Amgen has an open road for its Mvasi bevacizumab biosimilar after Genentech’s appeal to enjoin sales, over a notice of commercial marketing technicality, was denied. The US firm continues to weigh up patent-infringement proceedings in separate actions.
Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.
Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection
Regeneron and NIAID kick off a Phase III prevention trial for antibody cocktail REGN-COV2.